Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Short-course Radiotherapy Followed by Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: the ShorTrip Study

NCT05253846 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT05253846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05253846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Short-course Radiotherapy Followed by Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: the ShorTrip Study
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 25, 2022
Completion date
October 30, 2028
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer